Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 601–700 of 1,000
Kishino, Y., Tohyama, S., Morita, Y., SOMA, Y., Tani, H., Okada, M., Kanazawa, H., & Fukuda, K. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.10.433 · Cited by 9
Blanco, C., Madej, T., Mangner, N., Hommel, J., Grimm, S., Knaut, M., Linke, A. H.-P., & Winzer, E. B. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14508 · Cited by 6
“17 All of these characteristics are re-lated to outcome in terms of HF hospitalization and death and are used for the prognostication of survival.”
BackgroundMethodVericiguat: A Fifth Cornerstone in the Treatment of Heart Failure with Reduced Ejection Fraction?
Hammer, A., Niessner, A., & Sulzgruber, P. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14549 · Cited by 6
Ferrannini, G., Benson, L., Lautsch, D., Dahlström, U., Lund, L. H., Savarese, G., & Carrero, J. J. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14613 · Cited by 7
“23 In the GALACTIC trial, where HFrEF patients were required to receive HF therapy at optimized doses, the median value was 2000 vs. 4150 ng/L in HFrEF patients in the present cohort, further stressing the importance of treatment implementation.”
Alfieri, M., Bruscoli, F., Vito, L. D., Giusto, F. D., Scalone, G., Marchese, P., Delfino, D., Silenzi, S., Martoni, M., Guerra, F., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040125 · Cited by 7
“…Of note, a significant benefit was not found for NT-proBNP values > 8000 pg/mL. with phosphodiesterase 5 inhibitors, long-acting nitrates or other sGCS like Symp-tomatic hypotension, syncope and the principal side effects were not different among groups [25,29]. riociguat should be avoided [28].”
BackgroundMaurer, M. S., Soman, P., Hernandez, A. F., García-Pavía, P., Signorovitch, J., Wei, L.-J., Hanna, M. A., Ruberg, F., Kittleson, M. M., Kazi, D. S., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02891-0 · Cited by 8
“Extrapolation of trial design elements from HF trials was also dis‑ cussed as a model for potential primary compos‑ ite endpoint construction, allowing outcomes other than overall survival to be drivers of the effect size [34, 35].”
Self-citationNæsheim, T., How, O.-J., & Myrmel, T. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420940897 · Cited by 8
“stimulator vericiguat in patients with heart failure with reduced ejection fraction already on established guideline heart failure therapy.(10) In theory, the sGC stimulators act directly on sGC and in concert with NO.”
BackgroundKanagala, P., & Squire, I. B. (2020) · Echo Research and Practice · doi:10.1530/erp-20-0029 · Cited by 7
Gallo, G., Rubattu, S. D., & Volpe, M. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00489-z · Cited by 7
Recent developments in cGMP research: From mechanisms to medicines and back
Łukowski, R., & Feil, R. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15824 · Cited by 6
Armstrong, P. W., Zheng, Y., Lund, L. H., Butler, J., Troughton, R. W., Emdin, M., Lam, C. S. P., Ponikowski, P. P., Blaustein, R. O., O’Connor, C. M., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010661 · Cited by 6
Self-citationCharacterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China
Wang, Q., Wang, G., Peng, J., Li, J., Ju, C., Pan, L., Xu, Z., Qian, J., Liu, Z., Wu, G., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2512427 · Cited by 6
“To date, its clinical utility has been supported by only a single randomized controlled trial (RCT), the VICTORIA trial, which demonstrated that vericiguat reduces the risk of cardiovascular death or hospitalization in HF patients with a left ventricular ejection fraction (LVEF) below 45% [10].”
Li, C., Jay, N. D., Zhang, S., Fang, X. D., Sharma, S., Catalano, K. A., Sridharan, V., Wang, Z., Zhao, L., Szustakowski, J. D., et al. (2025) · Advanced Genetics · doi:10.1002/ggn2.202500003 · Cited by 11
Karakas, M., Friede, T., Butler, J., Talha, K. M., Placzek, M., Asendorf, T., Diek, M., Nosko, A., Stas, A., Kluge, S., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3742 · Cited by 9
Self-citationExploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure
Gawryś, O., Kala, P., Šnorek, M., Melenovský, V., Corda, S., & Sandner, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117363 · Cited by 7
Shah, P. M., Zheng, Y., Pieske, B. M., Melenovský, V., Lam, C. S. P., Sliwa, K. S., Butler, J., Ezekowitz, J. A., deFilippi, C. R., O’Connor, C. M., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013166 · Cited by 8
Self-citationPediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future
Das, B. B. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44109 · Cited by 6
“%) and recent worsening HF events [30].”
Vericiguat treatment of heart failure: A systematic review and meta-analysis
Yang, H., Luo, C., Lan, W.-Q., & Tang, Y.-H. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i35.8330 · Cited by 6
Pulmonary Hypertension in Underrepresented Minorities: A Narrative Review
Contreras, J., Nussbaum, J. S., Cangialosi, P., Thapi, S., Radakrishnan, A., Hall, J., Ramesh, P., Trivieri, M. G., & Sandoval, A. F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010285 · Cited by 8
Hattori, Y., Hattori, K., Ishii, K., & Kobayashi, M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116232 · Cited by 6
Özen, Y., Özbay, M. B., Nriagu, B. N., Yakut, İ., Kanal, Y., Çetin, E. H. Ö., & Oktay, A. A. (2024) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2024.15044 · Cited by 7
“…in managing HF. 28 Furthermore, despite effective disease-modifying GDMT options, patients with HFrEF are at increased risk of cardiac arrhythmias and SCD. 4,5,29,30 Moreover, we still need well-established tools beyond conventional parameters (EF or QT interval) to predict arrhythmia risk.”
BackgroundNovel Therapies to Reduce Rehospitalization Risk in Worsening Heart Failure
Lima, I. G. C. V., Nunes, J. T., Godoy, L. C., McDonald, M., & Bocchi, E. A. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101451 · Cited by 11
Rosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.03.014 · Cited by 10
Kerr, B., Pharithi, R. B., Barrett, M., Halley, C. M., Gallagher, J., Ledwidge, M. T., & McDonald, K. (2021) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0043 · Cited by 6
What Is the Status of Regenerative Therapy in Heart Failure?
Kir, D., Patel, M. J., & Munagala, M. R. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01575-3 · Cited by 9
Self-citationSilva‐Cardoso, J., Fonseca, C., Franco, F., Morais, J., Ferreira, J., & Brito, D. A. (2021) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2021.07.009 · Cited by 16
Кобалава, Ж. Д., & Lazarev, P. V. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-3035 · Cited by 6
FoxO4 controls sGCβ transcription in vascular smooth muscle
Galley, J. C., Miller, M. P., Sanker, S., Liu, M., Sharina, I. G., Martin, E., Gomez, D. A., & Straub, A. C. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00551.2021 · Cited by 6
Tran, B.-A., Serag-Bolos, E. S., Fernandez, J., & Miranda, A. (2022) · Journal of pharmacy and practice · doi:10.1177/08971900221087096 · Cited by 6
“Patients were divided into 3 different cohorts based on evidence of worsening heart failure and time of deterioration, with (1) hospitalized within 3 months before randomization, (2) hospitalized 3 to 6 months before randomization, and (3) receiving intravenous diuretic therapy without hospitalization within the previ…”
BackgroundMethodInfluentialImamura, T., & Kinugawa, K. (2022) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2022.08.012 · Cited by 5
Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure
Greenberg, B. (2022) · Cardiology Discovery · doi:10.1097/cd9.0000000000000060 · Cited by 6
“The VICTORIA study assessed the efficacy and safety of vericiguat in 5050 patients with chronic symptomatic HF, LVEF 45%, and recently decompensated HF.[58] The primary outcome was a composite of death from cardiovascular causes or first hospitalization for HF.”
MethodInfluentialSudden cardiac death prevention in the era of novel heart failure medications
Koev, I., Yarkoni, M., Luria, D. M., Amir, O., & Biton, Y. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100281 · Cited by 7
“The VICTORIA trial evaluated vericiguat 10 mg daily (an oral soluble guanylate-cyclase stimulator) in patients with NYHA class II-IV and LVEF 45 % [10].”
BackgroundMethodIdentifying the patient with heart failure to be treated with vericiguat
Escobar, C., Fernández, A. E., Mayoral, A. R., Mirabet, S., González‐Costello, J., Gracia, J. R., Villota, J. N., Franco, Á. G., & Palomas, J. L. B. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2189857 · Cited by 7
“Table performed with data from references.(30,41) Abbreviations.”
BackgroundMethodResultInfluentialCarroll, A. M., FARR, M. A., Russell, S. D., Schlendorf, K. H., Truby, L., Gilotra, N. A., Vader, J. M., Patel, C. B., & DeVore, A. D. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.02.015 · Cited by 6
Regional Management of Worsening Heart Failure: Rationale and Design of the CHAIN-HF Registry
Shakoor, A., Emans, M. E., van Gent, M. W. F., Hendrix, A., Faber, N., Springeling, T., de Vette, L. C., Manintveld, O. C., Denham, R. N., van de Meerendonk, C. T. U., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14354 · Cited by 5
“Although novel therapies demonstrating efficacy in the WHF population are becoming increasingly available, determining barriers for implementation of current pharmacotherapy is even more relevant.(16,17) Even when GDMT is successfully implemented, the clinical”
BackgroundChronic heart failure: the role of di vericiguat
Caminiti, G., Sposato, B., & Volterrani, M. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad056 · Cited by 6
“The study enrolled patients with a very high risk of rehospitalization and death, despite being treated with optimal therapy.(6) The occurrence of the primary endpoint in the group with the highest risk, i.”
BackgroundResultInfluentialBelenkov, Y. N., & Kozhevnikova, M. V. (2023) · Kardiologiia · doi:10.18087/cardio.2023.5.n2422 · Cited by 8
Николаевна, К. О., Baranov, A. V., Sazhina, A. S., & Bogomolov, A. N. (2023) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202326051102 · Cited by 6
TO MARKET, TO MARKET–2021: SMALL MOLECULES
Araujo, E., Bell, I. M., Burckle, A. J., Koester, D. C., Manning, J. R., Caldwell, R. D., Castanedo, G. M., Green, S. A., Zeng, M., Debien, L., et al. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch24 · Cited by 7
Sen, S. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89415 · Cited by 6
Heart Failure Without a Reduced Ejection Fraction
Kumar, S., & Psotka, M. A. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89417 · Cited by 6
Montembeau, S. C., Rao, B., Mitchell, A. R., Speight, C. D., Allen, L. A., Halpern, S. D., Ko, Y., Matlock, D. D., Moore, M. A., Morris, A. A., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.11.013 · Cited by 6
Devadoss, R., Dhillon, G. S., Sharma, P., Verma, R. K., Munjal, R. S., & Kashyap, R. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11010015 · Cited by 10
“5 of 13 The di ff erence was notable after three months of treat-ment [21].”
BackgroundSerrano, J. A. M., Cigarroa-López, J. A., Mendoza, A. C., Ivey-Miranda, J. B., Zavala, G. H. M., Domínguez, L. O., Leal, S., Pombo-Bartelt, J. E., Garza, E. H. H., Leal, G. M., et al. (2024) · Drugs in Context · doi:10.7573/dic.2023-8-1 · Cited by 12
“54 Vericiguat is an oral guanylate cyclase stimulator that favours the formation of cyclic guanosine monophosphate, improving the formation of nitric oxide and leading to a reduction of oxidative stress, a condition that is common in patients with HF.”
Budget impact analyses for treatment of heart failure. A systematic review
Teimourizad, A., Jafari, A., & Esmaeilzadeh, F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10397-8 · Cited by 7
“Patients with HF may experience multiple worsening HF events (WHFE) which can result in longer hospital stays, high hospital readmission rates and increased mortality outcomes following hospitalization [4] despite the use of standard guideline-directed medical treatments [5].”
InfluentialWong, D. F., Seitz, F., Bauer, V. C., Gießmann, T., & Schulze, F. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03165-w · Cited by 6
“Thus, activation of sGC may result in hypotension (Aktories et al. 2013), which is a previously reported class effect of sGC modulators (Armstrong et al. 2020; Erdmann et al. 2013; Frey et al. 2018; Markham and Duggan 2021; Sawabe et al. 2019).”
BackgroundInfluentialSeth, S., Bauersachs, J., Mittal, S., Rastogi, V., Rajput, R., Gandotra, D., Gupta, R. K., Sahu, M., Pathak, S. N., Bhagwati, M. M., et al. (2023) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_32_23 · Cited by 6
Khan, M. S., Kristensen, S. L., Vaduganathan, M., Køber, L., Abraham, W. T., Desai, A. S., Solomon, S. D., Swedberg, K. B., Dickstein, K., Zile, M. R., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.02.015 · Cited by 7
Self-citationGalley, J. C., Hahn, S. A., Miller, M. P., Durgin, B. G., Jackson, E. K., Stocker, S. D., & Straub, A. C. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15522 · Cited by 7
Längst, N., Adler, J., Schweigert, O., Kleusberg, F. M., Santos, M. C., Knauer, A., Sausbier, M., Zeller, T., Ruth, P., & Łukowski, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189925 · Cited by 6
“For instance, NO-releasing compounds, such as glyceryl trinitrate, are used to relieve the chest pain caused by angina pectoris attacks [28], inhibitors of PDE5 are in use for the short-term treatment of erectile dysfunction [29], riociguat, a heme-dependent stimulator of NO-GC, is prescribed in patients with pulmonar…”
BackgroundAbboud, A., Nguonly, A., Bean, A., Brown, K., Chen, R. F., Dudzinski, D. M., Fiseha, N., Joice, M. G., Kimaiyo, D., Martin, M. R., et al. (2021) · Open Heart · doi:10.1136/openhrt-2021-001704 · Cited by 6
DeVore, A. D., Hill, C. L., Thomas, L. E., Albert, N. M., Butler, J., Patterson, J. H., Hernandez, A. F., Williams, F. B., Shen, X., Spertus, J. A., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13709 · Cited by 7
Self-citationCimino, G., Pancaldi, E., Tomasoni, D., Lombardi, C., Metra, M., & Adamo, M. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001409 · Cited by 6
Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study
Felker, G. M., North, R., Mulder, H. S., Jones, W. S., Anstrom, K. J., Patel, M. J., Butler, J., Ezekowitz, J. A., Lam, C. S. P., O’Connor, C. M., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062055 · Cited by 6
Self-citationNonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat
Himmel, H. M., Lagrutta, A., Vömel, M., Amin, R. P., Imredy, J. P., Johnson, T. J., Vinzing, M., Prescott, J. S., & Blaustein, R. O. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001368 · Cited by 8
Parlati, A. L. M., Basile, C., & Filardi, P. P. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad026 · Cited by 7
Renal function and vericiguat in heart failure patients: light at the end of the tunnel!
Abdin, A., & Böhm, M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2280 · Cited by 6
Acyl-ghrelin therapy for heart failure: already a novel inotrope or even more?
Jankowska, E. A., & Ponikowski, P. P. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad220 · Cited by 6
Self-citationImamura, T., & Kinugawa, K. (2024) · International Heart Journal · doi:10.1536/ihj.24-091 · Cited by 6
Ghandakly, E., Banga, A., & Kaw, R. K. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12070238 · Cited by 7
Jung, M., Lee, S. Y., Cho, Y. H., Bae, D., Lee, S., Lee, C. J., Son, J., Cho, J. Y., & Kim, E. J. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0037 · Cited by 5
“21,31) The 2025 updates account for changes in insurance coverage that impact the prescription of SGLT2i.”
Cardiovascular disease epidemiology and management in the elderly and very elderly
Galati, G., Андреевна, Г. О., Dacquino, G. M., Bravo, F. F., Genovese, L., & Pedretti, R. F. E. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf470 · Cited by 7
The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management
Alvi, A., Singamala, H., Gadde, S. S. V., & Javvaji, C. K. (2026) · Cureus · doi:10.7759/cureus.100993 · Cited by 11
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
“In contrast, vericiguat reduced cardiovascular death or HHF in recently desta-bilized HFrEF patients in the VICTORIA trial [55] and in a prespecified pooled analysis of VICTOR/VICTORIA (n = 11,155) compared to placebo (HR 0.91; 95% CI, 0.85 to 0.98; p = 0.0088) [56].”
InfluentialVagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction
Konstam, M. A., Udelson, J. E., Mann, D. L., DiCarlo, L. A., Butler, J., Ardell, J. L., Ferrari, G. M. D., KLEIN, H. U., Filippatos, G. S., Metra, M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.040 · Cited by 5
Self-citationNew approach to heart failure: Integrated traditional Chinese with Western medicine
Wang, Q., Cao, H.-S., Li, P., Li, C., Shi, Z.-X., & Ren, J. (2024) · Advanced Chinese Medicine · doi:10.1002/acm4.10 · Cited by 5
Chang, P., Lee, H., Wo, H.-T., Liu, H.-T., Wen, M., & Chou, C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301970 · Cited by 5
“Recently, a soluble guanylate cyclase (sGC) stimulator, vericiguat, has been proven to be beneficial in patients with HFrEF [5].”
Heart Failure with Mildly Reduced Ejection Fraction—A Phenotype Waiting to Be Explored
Nair, A., Tuan, L. Q., Jones-Lewis, N., Raja, D. C., Shroff, J. P., & Pathak, R. K. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050148 · Cited by 6
Management of patients with heart failure and chronic kidney disease
Wu, L., Rodríguez, M., Hachem, K. E., Tang, W. H. W., & Krittanawong, C. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10415-9 · Cited by 6
“The VICTORIA trial revealed vericiguat further lowers the risk for HF hospitalization or death from CV causes among patients with heart failure who received background GDMT [164].”
The clinical and pharmacoeconomic impact of established and novel heart failure therapies
Acquaro, M., Turco, A., & Luca, L. D. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae118 · Cited by 5
Botero, S. N. R., Martínez, M. R., Rubio, L. F., Álvarez, A. L., Balaguer, V. M., Escrivá, D. G., Sierra, E. C., Montagud, Á. S., & Pérez-Silvestre, J. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.02.006 · Cited by 5
Khounphinith, E., Zhou, Y., Yi, Z.-Q., Li, T., & Li, L. (2025) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.25.008 · Cited by 5
“The dosage gradient was formulated by referencing existing studies on various cardiovascular and metabolic disease models, while also accounting for the conversion of equivalent drug dosages between rat and human body surface areas [20,40].”
Kim, M., & Park, S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.008 · Cited by 6
Seferovic, P. M., Polovina, M. M., Milinković, I., Anker, S. D., Rosano, G. M. C., & Coats, A. J. S. (2021) · International Journal of Heart Failure · doi:10.36628/ijhf.2021.0013 · Cited by 5
Dębska-Kozłowska, A., Książczyk, M., & Lelonek, M. (2022) · Advances in Medical Sciences · doi:10.1016/j.advms.2022.01.003 · Cited by 6
Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
Milinković, I., Polovina, M. M., Coats, A. J. S., Rosano, G. M. C., & Seferovic, P. M. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.14 · Cited by 8
Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists
Pipilas, A. R., Martyn, T., & Lindenfeld, J. M. (2022) · Structural Heart · doi:10.1016/j.shj.2022.100082 · Cited by 6
Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction
Krittanawong, C., Rodriguez, M., Lui, M., Misra, A., Tang, W. H. W., Bozkurt, B., & Yancy, C. W. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.01.024 · Cited by 6
Vrachatis, D. A., Papathanasiou, K. A., Giotaki, S. G., Raisakis, K., Kaoukis, A., Kossyvakis, C., Theodorakis, A., Pediotidis, S., Avramides, D., Siasos, G., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230316142450 · Cited by 8
Fernández, A. E., Mayoral, A. R., Franco, Á. G., Villota, J. N., Mirabet, S., Gracia, J. R., González‐Costello, J., Palomas, J. L. B., & Escobar, C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2195540 · Cited by 5
“or HF hospitalization compared to placebo [45].”
BackgroundImpact of vericiguat on heart failure with reduced ejection fraction: a review
Vohra, M., Amir, M., Osoro, I., Sharma, A., & Kumar, R. (2023) · Global Health Journal · doi:10.1016/j.glohj.2023.07.004 · Cited by 7
Jarjour, M., & Ducharme, A. (2023) · Drugs in Context · doi:10.7573/dic.2023-5-6 · Cited by 7
Zhao, Y. W., Zang, B., & Wang, Q. (2023) · Shock · doi:10.1097/shk.0000000000002277 · Cited by 5
“Numerous large-scale clinical studies have confirmed the ability of sGC stimulators to reduce cardiovascular-related mortality and HF hospitalization rates in HFrEF patients (22,23).”
BackgroundKang, D.-W., Kang, S., Lee, K., Nam, K.-A., Kim, E.-S., Youn, J., & Park, S. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131786 · Cited by 7
Kawai, A., Nagatomo, Y., Iwashita, M., Nakazawa, R., Yumita, Y., Taruoka, A., Takefuji, A., Yasuda, R., Toya, T., Ikegami, Y., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14020201 · Cited by 8
“HFrEF according to accumulating evidence in the last three decades [2,3,5,8,71,72].”
BackgroundArayıcı, M. E., Güneş, H., Ellıdokuz, H., & Yılmaz, M. B. (2024) · Scientific Reports · doi:10.1038/s41598-024-57695-7 · Cited by 5
Gawryś, O., Jíchová, Š., Miklovič, M., Husková, Z., Kikerlová, S., Sadowski, J., Kollárová-Brázdová, P., Lenčová-Popelová, O., Hošková, L., Imig, J. D., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01865-7 · Cited by 6
“…critically important role of the NO/sGC/cGMP in the cardiorenal physiology and pathophysiology, targeting this pathway is currently considered as one of the most promising approaches to HFrEF treatment [77, 80, 81] and could have a large potential also for the treatment of chemotherapy-induced HF.”
BackgroundOda, H., Hayashi, Y., Oyanagi, N., Tanaka, K., Ozaki, K., Kashiwa, A., Hosaka, Y., Tsuchida, K., & Takahashi, K. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04189-z · Cited by 5
“…double-blind, randomized, controlled trial comparing vericiguat to placebo in patients with a history of GDMT use and severe HFrEF, including those with WHF, demonstrated the clinical benefit of vericiguat for reducing cardiovascular death or HF hospitalization, without severe adverse effects [13].”
MethodMoghaddam, N., Swiston, J. R., Tsang, M. Y. C., Levy, R. D., Lee, L., & Brunner, N. W. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.01.003 · Cited by 5
Acute heart failure treatment: a light at the end of the tunnel?
Cotter, G., Davison, B. A., Edwards, C., Takagi, K., Solal, A. C., & Mebazaa, A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2116 · Cited by 6
Ennezat, P. V., Alavi, Z., Jemtel, T. H. L., & Hansen, M. R. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001215 · Cited by 6
Efficacy and Safety of Vericiguat for Treatment of Heart Failure: A Systematic Review.
Shaikh, T., Jawed, S., Rahmat, Z., Ahmed, S. H., Waseem, S., Ullah, I., Irfan, M., & Asghar, M. S. (2023) · Current problems in cardiology · doi:10.1016/j.cpcardiol.2023.101586 · Cited by 5
Gauthier, V., Lafrance, M., Barthoulot, M., Rousselet, L., Montaye, M., Ferrières, J., Kai, S. H. Y., Biasch, K., Moitry, M., Amouyel, P., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.02.035 · Cited by 7
Pharmacological Therapy Optimization for Heart Failure: A Practical Guide for the Internist
Dimza, M., Kurup, V., Canha, C., Jimenez, A., Al‐Ani, M. A., Parker, A. M., Vilaro, J. R., Ahmed, M. M., & Aranda, J. M. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.033 · Cited by 5
Angélico‐Gonçalves, A., Leite, A. R., Neves, J. S., Saraiva, F. A., Brochado, L., Oliveira, A., Butler, J., Packer, M., Zannad, F. M., Vasques‐Nóvoa, F., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.05.032 · Cited by 6
Self-citationFerreira, J. P., Cleland, J. G. F., Lam, C. S. P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., Police, D. A. L., Pitt, B., Greenberg, B., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01830-1 · Cited by 6
Self-citationNew 2021 ESC/HFA heart failure guidelines. A practical comprehensive approach
Manito, N. (2022) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2022.02.006 · Cited by 6
Maggioni, A. P., & Andreotti, F. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008840 · Cited by 5
The state of the art in medical therapies for pediatric heart failure
Ahmed, H., & Rossano, J. W. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100292 · Cited by 4
Matsumoto, S., Nasu, T., Fujimoto, W., Kagiyama, N., Shiraishi, Y., Ishii, S., Ijichi, T., Nakazawa, G., Ikeda, T., Kanaoka, K., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.09.013 · Cited by 4
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.